FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.
What happened
FDA inspected Aspen SA Sterile Operations (Pty) Ltd., an Aspen Pharmacare Holdings Limited subsidiary, from September 9 to 17, 2024, and found significant current good manufacturing practice (CGMP) violations for sterile drug products. The letter cites missing impurity testing and specifications, poor aseptic practices and inadequate smoke studies/cleanroom design, failure to review electronic data and report failing filter integrity tests, and inadequate environmental monitoring. FDA also reviewed Aspen's October 8, 2024 response and found it inadequate.
What FDA found
Aspen did not set suitable specifications or test its sterile over-the-counter drugs for impurities at release and during stability.
21 CFR 211.160(b)Aspen did not follow adequate written procedures to prevent microbial contamination in sterile drugs; FDA observed poor aseptic practices and inadequate smoke studies and cleanroom design.
21 CFR 211.113(b)Operators reported only passing filter integrity results after multiple failures and did not review electronic raw data and audit trails before batch release.
21 CFR 211.68(b)Aspen did not adequately monitor environmental conditions in aseptic processing areas, including viable monitoring and non-viable particle monitoring locations.
21 CFR 211.42(c)(10)(iv)
What FDA wants
FDA tells Aspen to respond in writing within 15 working days describing corrective actions and prevention, and to email within 5 days to schedule a regulatory meeting. FDA also says Aspen must notify the office before resuming any U.S.-regulated drug manufacturing.
Who should pay attention
- brands and distributors that buy sterile ophthalmic or OTC drugs from this contract manufacturer
- pharmacies and patients supplied with Aspen sterile OTC eye products
- contract manufacturers and quality teams handling aseptic filling, environmental monitoring, and data integrity
This is a summary. Read the original letter on fda.gov.